REVEAL GENOMICS
Contact information
- Biomarkers
- In vitro diagnostics
- Medical devices
- Oncology
- Bioinformatics
- Biotechnolgy kits
- Genomics
REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.
REVEAL GENOMICS, S.L. is a spin-off company of Hospital Clínic of Barcelona, IDIBAPS, the University of Barcelona (U.B.), and the Vall d’Hebron Institute of Oncology (VHIO).
- HER2DX® is the first genomic tool for patients with HER2+ breast cancer. Evaluated in >5,000 patients. HER2DX® reveals:
- long-term relapse risk
- probability of therapy response
- tumor HER2 expression levels
- DNADX® analyzes tumor tissue or plasma circulating tumor DNA to identify clinically relevant biomarkers. The test provides Copy Number Alteration (CNA)-based molecular subtyping and reports Single Nucleotide Variants (SNVs), indels, and CNAs in breast cancer driver genes.
TNBCDX® is the first genomic test designed specifically for patients with early-stage TNBC. The test integrates clinical variables with key tumor and immune biological factors across 15 genes to provide a comprehensive risk assessment, guiding treatment decisions in a clinical setting.
Market Access
Personalized Medicine and Advanced Diagnostics
Advanced Therapies
R&D Support
Artificial Intelligence and New Technologies
Talent and Diversity
Communication
Internationalization